344 related articles for article (PubMed ID: 19606230)
1. Autophagy facilitates the development of breast cancer resistance to the anti-HER2 monoclonal antibody trastuzumab.
Vazquez-Martin A; Oliveras-Ferraros C; Menendez JA
PLoS One; 2009 Jul; 4(7):e6251. PubMed ID: 19606230
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells.
Vazquez-Martin A; Colomer R; Brunet J; Menendez JA
Int J Oncol; 2007 Oct; 31(4):769-76. PubMed ID: 17786307
[TBL] [Abstract][Full Text] [Related]
3. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells.
Vazquez-Martin A; Oliveras-Ferraros C; Del Barco S; Martin-Castillo B; Menendez JA
Breast Cancer Res Treat; 2011 Apr; 126(2):355-64. PubMed ID: 20458531
[TBL] [Abstract][Full Text] [Related]
4. Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin) in HER2-overexpressing breast cancer cells.
Menendez JA; Vazquez-Martin A; Colomer R; Brunet J; Carrasco-Pancorbo A; Garcia-Villalba R; Fernandez-Gutierrez A; Segura-Carretero A
BMC Cancer; 2007 May; 7():80. PubMed ID: 17490486
[TBL] [Abstract][Full Text] [Related]
5. Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.
Cufí S; Vazquez-Martin A; Oliveras-Ferraros C; Corominas-Faja B; Urruticoechea A; Martin-Castillo B; Menendez JA
Oncotarget; 2012 Dec; 3(12):1600-14. PubMed ID: 23307622
[TBL] [Abstract][Full Text] [Related]
6. Autophagy flux inhibition augments gastric cancer resistance to the anti-human epidermal growth factor receptor 2 antibody trastuzumab.
Ye H; Chai X; Wang X; Zheng Q; Zheng D; Wu F; Zheng C; Chen P
Oncol Lett; 2018 Apr; 15(4):4143-4150. PubMed ID: 29541179
[TBL] [Abstract][Full Text] [Related]
7. Autophagy facilitates the development of resistance to the tumor necrosis factor superfamily member TRAIL in breast cancer.
Lv S; Wang X; Zhang N; Sun M; Qi W; Li Y; Yang Q
Int J Oncol; 2015 Mar; 46(3):1286-94. PubMed ID: 25572822
[TBL] [Abstract][Full Text] [Related]
8. Inhibitor of Apoptosis (IAP) survivin is indispensable for survival of HER2 gene-amplified breast cancer cells with primary resistance to HER1/2-targeted therapies.
Oliveras-Ferraros C; Vazquez-Martin A; Cufí S; Torres-Garcia VZ; Sauri-Nadal T; Barco SD; Lopez-Bonet E; Brunet J; Martin-Castillo B; Menendez JA
Biochem Biophys Res Commun; 2011 Apr; 407(2):412-9. PubMed ID: 21402055
[TBL] [Abstract][Full Text] [Related]
9. Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: new insights into de novo resistance to trastuzumab (Herceptin).
Oliveras-Ferraros C; Vazquez-Martin A; Martin-Castilló B; Pérez-Martínez MC; Cufí S; Del Barco S; Bernado L; Brunet J; López-Bonet E; Menendez JA
Int J Oncol; 2010 Sep; 37(3):669-78. PubMed ID: 20664936
[TBL] [Abstract][Full Text] [Related]
10. Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin).
Oliveras-Ferraros C; Vazquez-Martin A; Martin-Castillo B; Cufí S; Del Barco S; Lopez-Bonet E; Brunet J; Menendez JA
Biochem Biophys Res Commun; 2010 Jun; 397(1):27-33. PubMed ID: 20470755
[TBL] [Abstract][Full Text] [Related]
11. The anti-malarial chloroquine overcomes primary resistance and restores sensitivity to trastuzumab in HER2-positive breast cancer.
Cufí S; Vazquez-Martin A; Oliveras-Ferraros C; Corominas-Faja B; Cuyàs E; López-Bonet E; Martin-Castillo B; Joven J; Menendez JA
Sci Rep; 2013; 3():2469. PubMed ID: 23965851
[TBL] [Abstract][Full Text] [Related]
12. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
Menendez JA; Vellon L; Lupu R
Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
[TBL] [Abstract][Full Text] [Related]
13. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
[TBL] [Abstract][Full Text] [Related]
14. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
15. Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing.
Kute TE; Savage L; Stehle JR; Kim-Shapiro JW; Blanks MJ; Wood J; Vaughn JP
Cancer Immunol Immunother; 2009 Nov; 58(11):1887-96. PubMed ID: 19340424
[TBL] [Abstract][Full Text] [Related]
16. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.
Osipo C; Patel P; Rizzo P; Clementz AG; Hao L; Golde TE; Miele L
Oncogene; 2008 Aug; 27(37):5019-32. PubMed ID: 18469855
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-overexpressing breast cancer cell line.
Chen W; Wei F; Xu J; Wang Y; Chen L; Wang J; Guan X
Int J Mol Med; 2011 Dec; 28(6):985-91. PubMed ID: 21887460
[TBL] [Abstract][Full Text] [Related]
18. Development and Characterization of a Humanized Anti-HER2 Antibody HuA21 with Potent Anti-Tumor Properties in Breast Cancer Cells.
Li R; Hu S; Chang Y; Zhang Z; Zha Z; Huang H; Shen G; Liu J; Song L; Wei W
Int J Mol Sci; 2016 Apr; 17(4):563. PubMed ID: 27092488
[TBL] [Abstract][Full Text] [Related]
19. Sensitization of breast cancer cells to radiation by trastuzumab.
Liang K; Lu Y; Jin W; Ang KK; Milas L; Fan Z
Mol Cancer Ther; 2003 Nov; 2(11):1113-20. PubMed ID: 14617784
[TBL] [Abstract][Full Text] [Related]
20. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.
Shak S
Semin Oncol; 1999 Aug; 26(4 Suppl 12):71-7. PubMed ID: 10482196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
